CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Peripheral blood drawWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug357 Humanistic Care Wiki 1.00
drug707 Ruxolitinib Wiki 0.45

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Pilot Study of Ruxolitinib to Combat COVID-19

The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.

NCT04354714 COVID-19 Drug: Ruxolitinib Procedure: Peripheral blood draw

Primary Outcomes

Measure: Overall survival

Time: Through 28 days

Secondary Outcomes

Measure: Length of hospital stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Length of ICU stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of ventilator use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of vasopressors use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration on renal replacement therapy

Time: Through completion of follow-up (estimated to be 7 months)

Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing

Measure: Viral kinetics as measured by virologic failure

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Number of adverse events as measured by CTCAE v. 5.0

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Proportion of participants with detectable virus

Time: Day 5

Measure: Proportion of participants with detectable virus

Time: Day 10

Measure: Proportion of participants with detectable virus

Time: Day 15

Measure: Proportion of participants with detectable virus

Time: Day 29

No related HPO nodes (Using clinical trials)